Development and evaluation of paclitaxel nanoparticles using a quality-by-design approach

Journal of Pharmaceutical Sciences

Volumn 102, Issue 10, 2013, Pages 3748-3761

  Yerlikaya, Firat ^a   Ozgen, Aysegul ^a   Vural, Imran ^a   Guven, Olgun ^a   Karaagaoglu, Ergun ^a   Khan, Mansoor A ^b   Capan, Yilmaz ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Box Behnken; Design of experiments; Formulation; Mathematical model; Multivariate analysis; Nanoparticles; Paclitaxel; Plackett Burman; Polymeric drug delivery systems; Quality by design

Indexed keywords

NANOPARTICLE; PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ATOMIC FORCE MICROSCOPY; BREAST CARCINOMA; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG RELEASE; FIELD EMISSION SCANNING ELECTRON MICROSCOPY; HUMAN; HUMAN CELL; IN VITRO STUDY; INFRARED SPECTROSCOPY; NANOENCAPSULATION; PARTICLE SIZE; RISK ASSESSMENT; THERMOGRAVIMETRY; X RAY DIFFRACTION; ZETA POTENTIAL;

BOX-BEHNKEN; DESIGN OF EXPERIMENTS; FORMULATION; MATHEMATICAL MODEL; MULTIVARIATE ANALYSIS; NANOPARTICLES; PACLITAXEL; PLACKETT-BURMAN; POLYMERIC DRUG DELIVERY SYSTEMS; QUALITY BY DESIGN;

ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; NANOPARTICLES; PACLITAXEL; PARTICLE SIZE;

EID: 84883748038     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23686     Document Type: Article

References (40)

1. US FDA. 2004. Guidance for industry: PAT-A framework for innovative pharmaceutical development, manufacturing, and quality assurance. Silver Spring, Maryland: US FDA.
2. ICH. 2009. Q8(R2): Pharmaceutical Development. Geneva, Switzerland: ICH.
3. Awotwe-Otoo D, Agarabi C, Faustino PJ, Habib MJ, Lee S, Khan MA, Shah RB. 2012. Application of quality by design elements for the development and optimization of an analytical method for protamine sulfate. J Pharm Biomed Anal 62:61-67.
4. Mockus LN, Paul TW, Pease NA, Harper NJ, Basu PK, Oslos EA, Sacha GA, Kuu WY, Hardwick LM, Karty JJ, Pikal MJ, Hee E, Khan MA, Nail SL. 2011. Quality by design in formulation and process development for a freeze-dried, small molecule parenteral product: A case study. Pharm Dev Technol 16(6):549-576.
5. Shah RB, Zidan AS, Funck T, Tawakkul MA, Nguyenpho A, Khan MA. 2007. Quality by design: Characterization of self-nano-emulsified drug delivery systems (SNEDDs) using ultrasonic resonator technology. Int J Pharm 341(1-2):189-194.
6. Verma S, Lan Y, Gokhale R, Burgess DJ. 2009. Quality by design approach to understand the process of nanosuspension preparation. Int J Pharm 377(1-2):185-198.
7. Wu H, Khan MA. 2009. Quality-by-design (QbD): An integrated approach for evaluation of powder blending process kinetics and determination of powder blending end-point. J Pharm Sci 98(8):2784-2798.
8. Wu H, Khan MA. 2010. Quality-by-design (QbD): An integrated process analytical technology (PAT) approach for real-time monitoring and mapping the state of a pharmaceutical coprecipitation process. J Pharm Sci 99(3):1516-1534.
9. Wu H, Tawakkul M, White M, Khan MA. 2009. Quality-by-design (QbD): An integrated multivariate approach for the component quantification in powder blends. Int J Pharm 372(1-2):39-48.
10. Xie L, Wu H, Shen M, Augsburger LL, Lyon RC, Khan MA, Hussain AS, Hoag SW. 2008. Quality-by-design (QbD): Effects of testing parameters and formulation variables on the segregation tendency of pharmaceutical powder measured by the ASTM D 6940-04 segregation tester. J Pharm Sci 97(10):4485-4497.
11. Xu X, Costa AP, Khan MA, Burgess DJ. 2012. Application of quality by design to formulation and processing of protein liposomes. Int J Pharm 434(1-2):349-359.
12. Xu X, Khan MA, Burgess DJ. 2012. A quality by design (QbD) case study on liposomes containing hydrophilic API: II. Screening of critical variables, and establishment of design space at laboratory scale. Int J Pharm 423(2):543-553.
13. Zidan AS, Sammour OA, Hammad MA, Megrab NA, Habib MJ, Khan MA. 2007. Quality by design: Understanding the product variability of a self-nanoemulsified drug delivery system of cyclosporine A. J Pharm Sci 96(9):2409-2423.
14. Vanaja K, Shobha Rani RH 2007. Design of experiments: Concept and applications of Plackett-Burman design. Clin Res Regul Aff 24(1):1-23.
15. Awotwe-Otoo D, Agarabi C, Wu GK, Casey E, Read E, Lute S, Brorson KA, Khan MA, Shah RB. 2012. Quality by design: Impact of formulation variables and their interactions on quality attributes of a lyophilized monoclonal antibody. Int J Pharm 438(1-2):167-175.
16. Box GEP, Behnken DW. 1960. Some new three level designs for the study of quantitative variables. Technometrics 2(4):455-475.
17. Khan MA, Sastry SV, Vaithiyalingam SR, Agarwal V, Nazzal S, Reddy IK. 2000. Captopril gastrointestinal therapeutic system coated with cellulose acetate pseudolatex: Evaluation of main effects of several formulation variables. Int J Pharm 193(2):147-156.
18. Plackett RL, Burman JP. 1946. The design of optimum multifactorial experiments. Biometrika 33(4):305-325.
19. Rahman Z, Zidan AS, Habib MJ, Khan MA. 2010. Understanding the quality of protein loaded PLGA nanoparticles variability by Plackett-Burman design. Int J Pharm 389(1-2):186-194.
20. Zidan AS, Sammour OA, Hammad MA, Megrab NA, Habib MJ, Khan MA. 2007. Quality by design: Understanding the formulation variables of a cyclosporine A self-nanoemulsified drug delivery systems by Box-Behnken design and desirability function. Int J Pharm 332(1-2):55-63.
21. Wang C, Wang Y, Wang Y, Fan M, Luo F, Qian Z. 2011. Characterization, pharmacokinetics and disposition of novel nanoscale preparations of paclitaxel. Int J Pharm 414(1-2):251-259.
22. Cun D, Jensen DK, Maltesen MJ, Bunker M, Whiteside P, Scurr D, Foged C, Nielsen HM. 2011. High loading efficiency and sustained release of siRNA encapsulated in PLGA nanoparticles: Quality by design optimization and characterization. Eur J Pharm Biopharm 77(1):26-35.
23. Xu Q, Crossley A, Czernuszka J. 2009. Preparation and characterization of negatively charged poly(lactic-co-glycolic acid) microspheres. J Pharm Sci 98(7):2377-2389.
24. Bhardwaj V, Ankola DD, Gupta SC, Schneider M, Lehr CM, Kumar MNVR. 2009. PLGA nanoparticles stabilized with cationic surfactant: Safety studies and application in oral delivery of paclitaxel to treat chemical-induced breast cancer in rat. Pharm Res 26(11):2495-2503.
25. Kollipara S, Bende G, Movva S, Saha R. 2010. Application of rotatable central composite design in the preparation and optimization of poly(lactic-co-glycolic acid) nanoparticles for controlled delivery of paclitaxel. Drug Dev Ind Pharm 36(11):1377-1387.
26. Bodmeier R, McGinity JW. 1987. The preparation and evaluation of drug-containing poly(dl-lactide) microspheres formed by the solvent evaporation method. Pharm Res 4(6):465-471.
27. Xu X, Khan MA, Burgess DJ. 2011. A quality by design (QbD) case study on liposomes containing hydrophilic API: I. Formulation, processing design and risk assessment. Int J Pharm 419(1-2):52-59.
28. Yang T, Cui FD, Choi MK, Cho JW, Chung SJ, Shim CK, Kim DD. 2007. Enhanced solubility and stability of PEGylated liposomal paclitaxel: In vitro and in vivo evaluation. Int J Pharm 338(1-2):317-326.
29. Gao CL, Pan J, Lu WY, Zhang M, Zhou L, Tian J. 2009. In-vitro evaluation of paclitaxel-loaded MPEG-PLGA nanoparticles on laryngeal cancer cells. Anticancer Drug 20(9):807-814.
30. Sarisozen C, Vural I, Levchenko T, Hincal AA, Torchilin VP. 2012. PEG-PE-based micelles co-loaded with paclitaxel and cyclosporine A or loaded with paclitaxel and targeted by anticancer antibody overcome drug resistance in cancer cells. Drug Deliv 19(4):169-176.
31. Alipour S, Montaseri H, Tafaghodi M. 2010. Preparation and characterization of biodegradable paclitaxel loaded alginate microparticles for pulmonary delivery. Colloids Surf B Biointerfaces 81(2):521-529.
32. Langenbucher F. 1972. Linearization of dissolution rate curves by the Weibull distribution. J Pharm Pharmacol 24(12):979-981.
33. Yang Q, Owusu-Ababio G 2000. Biodegradable progesterone microsphere delivery system for osteoporosis therapy. Drug Dev Ind Pharm 26(1):61-70.
34. Jackson JK, Hung T, Letchford K, Burt HM. 2007. The characterization of paclitaxel-loaded microspheres manufactured from blends of poly(lactic-co-glycolic acid) (PLGA) and low molecular weight diblock copolymers. Int J Pharm 342(1-2):6-17.
35. Wischke C, Schwendeman SP. 2008. Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. Int J Pharm 364(2):298-327.
36. Costa P, Manuel J, Lobo S. 2001. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 13(2):123-133.
37. Feng SS, Huang GF. 2001. Effects of emulsifiers on the controlled release of paclitaxel (Taxol (R)) from nanospheres of biodegradable polymers. J Control Release 71(1):53-69.
38. ICH. 2009. Q3C(R4) Impurities: Guideline for residual solvents. Geneva, Switzerland: ICH.
39. Dong X, Mattingly CA, Tseng MT, Cho MJ, Liu Y, Adams VR, Mumper RJ. 2009. Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP Cancer Res 69(9):3918-3926.
40. Shin JY, Yang Y, Heo P, Lee JC, Kong B, Cho JY, Yoon K, Shin CS, Seo JH, Kim SG, Kweon DH. 2012. pH-responsive high-density lipoprotein-like nanoparticles to release paclitaxel at acidic pH in cancer chemotherapy. Int J Nanomedicine 7:2805-2816.